NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee C) meeting minutes

**Minutes:** Unconfirmed

**Date and time:** Wednesday 2 December 2020 at 9:30am

**Location:** Via Zoom

## **Committee members present**

1. Steve O’Brien (Chair) Present for all items
2. Peter Selby (Vice Chair) Present for all items
3. Mike Chambers Present for all items
4. Prithwiraj Das Present for items 1 to 2.4.2
5. David Foreman Present for all items
6. Natalie Hallas Present for all items
7. Nigel Langford Present for all items
8. Andrea Manca Present for all items
9. Iain McGowen Present for all items
10. Kirandip Moyo Present for all items
11. Mudasar Mushtaq Present for items 1 to 2.4.2
12. Richard Nicholas Present for items 1 to 2.4.2
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Subhash Pokhrel Present for all items
16. Andrew Renehan Present for all items
17. Matt Stevenson Present for all items
18. Paul Tappenden Present for all Items

## **NICE staff present:**

Ross Dent, Associate Director Present for all items

Jasdeep Hayre, Associate Director Present for items 3 to 3.2.3

Louise Jafferally, Project Manager Present for all items

Victoria Kelly, HTA Adviser Present for items 1 to 2.4.2

Luke Cowie, HTA Analyst Present for items 1 to 2.4.2

Verena Wolfram, HTA Analyst Present for items 3 to 3.2.3

Catherine Pank, MIP Coordinator Present for items 1 to 2.3

Gemma Smith, COT Coordinator Present for all items

Laura Marsden, Public Involvement Adviser Present for items 1 to 2.3

Mandy Tonkinson, Public involvement Adviser Present for items 1 to 2.3

Sophie McHugh, COT Administrator Present for all items

Dawn Abbott, MIP Office Assistant Present for items 1 to 2.4.2.

## **External group representatives present:**

Janette Greenhalgh, Liverpool Reviews and Implementation Group, University of Liverpool Present for items 1 to 2.3

James McMahon, Liverpool Reviews and Implementation Group, University of Liverpool Present for items 1 to 2.3

## **Professional experts present:**

Eslam Al-Abadi, Consultant Paediatric Rheumatologist, Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Present for items 1 to 2.3

Lisa Dunkley, Consultant Adult & Adolescent Rheumatologist, Sheffield Teaching Hospitals NHSFT, Present for items 1 to 2.3

Amanda Jones, Patient expert, nominated by Rare Autoinflammatory Conditions Community – UK (RACCUK), Present for items 1 to 2.3

Paul McManus, Senior Pharmacist, NHS England Specialised Commissioning, Present for items 1 to 2.3

Rachel Rimmer, Founder & Chair of Rare Autoinflammatory Conditions Community – UK (RACC-UK), Present for items 1 to 2.3

## **Observers present:**

Helen Barnett, Senior Medical Editor, NICE, Present for items 1 to 2.4.2

Sarah Bromley, Senior Medical Editor, NICE, Present for items 3 to 3.2.3

Gareth Murphy, Business Analyst, NICE, Present for all items

Christopher Flood, Content Strategy Lead, NICE, Present for items 1 to 2.4.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment, NICE, Present for all items

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.

### Appraisal of Anakinra for treating Still's disease (ID1463)

* 1. **Part 1 – Open session**
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Swedish Orphan Biovitrum Ltd
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Michael Chambers declared a financial interest as he is currently helping to co-ordinate a training programme on Real World Evidence for Roche pharmaceuticals (manufacturer of a potential comparator): this has not involved specific consideration of any Roche products.
* It was agreed that Michael’s declaration would not prevent him from participating in this section of the meeting.
* Prithwiraj Das declared a non-financial professional & personal Interests as he works at the pharmaceutical company Boehringer Ingelheim Ltd as the Market Access Lead for Specialty Therapies. He has not worked in the indication under consideration.
* It was agreed that Prithwiraj’s declaration would not prevent him from participating in this section of the meeting.
* Richard Nicholas declared a financial interest as he has performed advisory boards and is a PI of clinical trials for Novartis in the condition Multiple Sclerosis.
* It was agreed that Richard’s declaration would not prevent him from participating in this section of the meeting
* Amanda Jones declared a personal interest as she was a participant in a Still’s disease video campaign funded by Sofi.
* It was agreed that Amanda’s declaration would not prevent her from providing expert advice to the committee in part one of the meeting.
* Dr Eslam Al-Abadi declared a financial interest as had received Speaker fees for a talk about sJIA on the 8th of September 2020 for the organisation Rare Matters.
* It was agreed that Eslam’s declaration would not prevent him from providing expert advice to the committee in part one of the meeting.
* Lisa Dunkley declared a financial interest as she has previously received honoraria for teaching/ speaker’s fees from UCB, Pfizer & Abbvie but none since 2019.
* It was agreed that Lisa’s declaration would not prevent her from providing expert advice to the committee in part one of the meeting.
* No further conflicts of interest were declared for this appraisal.
  1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. **Part 2 – Closed session** (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of Selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma

1. Part 2 – closed session
   * 1. The chair welcomed the committee members and NICE staff
     2. The chair asked all committee members and NICE staff present to declare any relevant interests in relation to the item being considered.

* Andrew Renehan declared an indirect interest as his workplace is one of a limited number of centres where SIRT is performed but he has no direct involvement in this.
* It was agreed that Andrew’s declaration would not prevent him from participating in this section of the meeting.
* No further conflicts of interest were declared for this appraisal
  1. The Chair introduced the information which has been submitted since the previous Committee meeting.
     1. The committee discussed the confidential information submitted for this item.
     2. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Tuesday 12 January 2021.